Asp3082 clinical trial. Clinical trial identification.

Asp3082 clinical trial Notably, although the Genes contain genetic code which tell the body which proteins to make. Open in viewer. This information will help find a suitable dose and to check for potential medical problems from the We would like to show you a description here but the site won’t allow us. What Is ASP3082? ASP3082 is a protein degrader that acts as a link by binding specifically to KRAS G12D and at the same time to the protein degradation machinery, which being linked/in close proximity to KRAS G12D can tag it for degradation stopping its activities. Enrollment Goal. Clinical trials look at new ways to HLA restriction suggests that RO7617991 resembles a T-cell receptor, but the clinical trial entry makes no mention of lymphodepletion or apheresis, suggesting this isn’t a cell therapy. HRS-4642. 435 Studies Now Enrolling. Before ASP3082 is available as a treatment, the researchers need Clinical Trials Search at Vanderbilt-Ingram Cancer Center. ASP3082 (ClinicalTrials. There are clinics nationwide conducting this trial so you should look into it. Seeking perspective. You may want to think about taking part in a clinical trial. Print. ClinicalTrials. Clinical trial information: NCT04858334. View Complete Trial Details & Eligibility at ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Metastatic means the cancer has spread to other parts of the body. Before ASP3082 is available as a treatment, the researchers need. S. ASP-3082 overview. Search for terms Degrader (ASP3082) @30 mg/kg IV twice a week Xenograft mice bearing human pancreatic cancer with KRAS G12D mutation 1500 1000 500 0 0 5 10 15 m 3) KRAS Inhibitor (PO) PK-59 cell (KRAS G12D positive) Tumor cell implantation KRAS Degrader (IV) ASP3082 Days KRAS: Kirsten rat sarcoma viral oncogene homologue, PO: oral administration, IV Find a clinical trial. 21일 주기 세툭시맙- 주 1회, 정맥내주입 asp3082와 표준 항암화학요법 병용요법 - 28일 주기 1차 유효성 평가변수 Clinical data from lead pipeline assets: Phase 1 data from ASP3082, the first protein degrader targeting KRAS G12D mutant to enter clinical trials, in patients with advanced pancreatic, colorectal • Clinical data from lead pipeline assets: Phase 1 data from ASP3082, the first protein degrader targeting KRAS G12D mutant to enter clinical trials, in patients with advanced pancreatic, colorectal, and non-small cell lung cancer; and preclinical, translational/early clinical data from ASP1570, a novel DGKζ Find a Clinical Trial Find a Physician Find a Location Carespace For Patients and Caregivers Treatments Cancers We Treat Bispecific Therapy Chemotherapy Clinical Trials Hematology Immunotherapy Infusion Therapy Pathology The oral, covalent, mutant-selective KRAS inhibitor, RMC-9805, has been dosed for the first time in a patient with a KRAS-G12D-mutant solid tumor, marking the beginning of a phase 1/1b clinical trial (NCT06040541). ≥18. ASP3082 is in Phase 1 trials for the treatment of solid tumors harboring the KRAS G12D mutation, having demonstrated a superior anti-tumor effect in preclinical studies when compared to conventional small molecule inhibitors. Co-targeting CDK2 and CDK4/6 can overcome resistance to aromatase and CDK4/6 inhibitors in hormone receptor positive breast Background: Kirsten rat sarcoma (KRAS) G12D is a point mutation observed in various cancer types including pancreatic ductal cancer, colon adenocarcinoma, and lung cancers. Identify the latest clinical trials across global registries. On a molecular level, ASP3082 has a dumbbell-like Apply to this Phase 1 clinical trial treating Tumors, Solid. ASP4396 is being Clinical Trials Search at Vanderbilt-Ingram Cancer Center. Before ASP3082 is available as a treatment, the A phase 2 clinical trial of sotorasib reported an ORR of 9. Howev-er, at this stage, a number of points are clear about the clinical ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. NEXT ARTICLE. Editorial acknowledgement: Editorial support was provided by Haniya Javaid of Background: ASP3082 is a novel protein degrader selectively targeting KRAS G12D. Before ASP3082 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. gov identifier: NCT05382559) and MRTX1133 (ClinicalTrials. The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors TPS764 Trials in Progress Poster Session Trialinprogress:Aphase 1,first-in-human, open-label,multicenter,dose-escalationand dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations. 22 310 A Phase I Study of ASP3082 in People with Solid Tumors with KRAS G12D Mutations; You can see a current listing of MSK’s clinical trials for No New Molecular Entity Yes Highest Development Phases Phase I Cancer; Solid tumours Most Recent Events 14 Apr 2023 Pharmacodynamics data from a preclinical trial in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023) ; 26 Oct 2022 Astellas pharma presented pharmacodynamics data from a ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models (AACR-NCI-EORTC 2022) - P1 | "ASP3082 is a potential therapeutic agent for patients with tumors harboring the KRAS G12D mutation. The clinical ranks will now be swelled by Lilly’s LY3962673, which had preclinical data at this year The second is to find a suitable dose of ASP3082 to use in future studies. Immunotherapy, Monoclonal Antibody, Signal Transduction Inhibitor. gov identifier: NCT05737706) are two drugs with open phase I trials targeting KRAS G12D, a mutation that is found in about 35% of Clinical data from lead pipeline assets: Phase 1 data from ASP3082, the first protein degrader targeting KRAS G12D mutant to enter clinical trials, in patients with advanced pancreatic, colorectal, and non-small cell lung cancer; and preclinical, translational/early clinical data from ASP1570, a novel DGKζ inhibitor, in patients with advanced ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Solid Tumor United States, Japan, France, Spain, Korea, Republic of National Cancer Institute (NCI) Recruiting Clinical Trials Office Register as a Researcher Log In. gov ID: NCT05382559. ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. gov Clinical trials look at new ways to prevent, detect, or treat disease. Clinical Trial. I feel very good right now and want to ride that wave as long as possible. Very little is known about ASP3082, though Astellas noted its advancement into the clinic in 2022, at a time when more typical inhibition of KRAS G12D was already becoming a competitive area. NCT05382559. “Once we ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Herein, we designed a series of potent inhibitors that can form ASP3082 is a potential therapeutic agent for patients with tumors harboring the KRAS G12D mutation. Genetic Testing; Cancer Screening for First Responders; Community Outreach & Engagement Center; ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Clinical trials look at new ways to The next step for the drug is clinical trials. In Part 1, different small groups of people will receive lower to higher doses of ASP3082. 7% and a median PFS of 4. Here, we describe the preliminary safety and antitumor activity of ASP3082 monotherapy in patients (pts) with ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations. Adult patients with any solid t Based on the results of a single-arm phase 2 clinical trial, ASP3082 is a KRAS G12D PROTAC developed by Astellas Pharma and the phase 1 study is ongoing (NCT05382559) [85, 86]. ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Brief Summary Brief Summary. Login. Any medical problems will be recorded at each dose. ASP3082 is a novel protein degrader selectively targeting KRAS G12D. Clinical trial identification. Greco-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in asp3082- 정맥 내 주입. ASP3082 experienced an expedited R&D process as it was targeting the KRAS G12D mutation. Purpose Clinical Trials Search at Vanderbilt-Ingram Cancer Center. 0 months, ASP3082, a selective KRAS G12D degrader, is currently furthest along in clinical development. to study the efficacy and safety of the drug for pancreatic cancer, colorectal cancer, and lung cancer with KRAS G12D mutation. Some types of cancer are caused by changes, or mutations, in a gene called KRAS. To date, however, clinical data Clinical trial identification: NCT05208762. Study record managers: refer to the Data Element Definitions if submitting registration or results information. You can view the full content in the 国立がん研究センター中央病院 先端医療科が実施している治験の概要や参加条件をご紹介しています。この試験は、標準治療後の進行性固形がんを対象にした第I臨床試験で、KRAS G12D阻害剤の単独療法、または、EGFR阻害剤との併用療法を投与する臨床試験です。 Results from the correlative analyses will inform future clinical trial design for this novel treatment combination in patients with dedifferentiated liposarcoma. (Participants who are currently in the follow-up period of an interventional clinical trial are allowed Browse Trials. Astellas is also investigating the use of ASP3082 in combination with the EGFR-blocking antibody cetuximab in Phase I trials, with encouraging results indicating the potential of combining EGFR ESMO abstract data showed underwhelming results for Astellas’s first-in-class KRAS G12D degrader ASP3082, but the company is pressing on. Modalities. Currently, at least nine KRAS G12D-selective inhibitors are under clinical evaluation (ASP3082, ASP4396, GFH375/VS-7375, HRS-4642, INCB161734, MRTX1133, QTX3046, RMC-9805, and TSN1611). ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models (AACR-NCI-EORTC 2022) - P1 | "ASP3082 is a potential therapeutic agent for patients with tumors harboring the KRAS G12D mutation. Activation of CDK4/6 is implicated in breast, ovarian and non-small cell lung cancers, among others (FASEB J. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. Currently, a phase 1 clinical trial is underway in patients with previously treated, locally advanced or metastatic solid tumors with KRAS G12D mutation (NCT05382559). This first-in-human (FIH), phase I, multicenter, open-label study was conducted to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy, and to establish the MTD/recommended dose for expansion (RDE) of PCA062 in patients with solid tumors. ASP-3082 is under development for the treatment of solid tumors including pancreatic ductal adenocarcinoma, metastatic colorectal cancer, non-small cell lung cancer. This work is licensed under a ASP3082. However, there is no direct KRAS The competition, meanwhile, includes Mirati’s MRTX1133 and Astellas’s degrader project ASP3082, as well as engineered T-cell receptor approaches at the NCI (this had been in Kite’s pipeline, so Gilead presumably has some rights over it), Medigene and the private companies Affini-T and Anocca. 1 11 Our lead program, ASP3082, is the first protein degrader for mutated KRAS G12D to enter the clinic 1. ASP3082 is a potential new treatment for certain solid tumors in people who have the G12D mutation in their KRAS gene. Before ASP3082 is available as a treatment, the researchers need A Study of ASP3082 in Adults With Previously Treated Solid Tumors. Screening and Prevention. Talk to your doctor for help in deciding if one is right for you. Search by Keyword (disease, investigator, treatment name): Search. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Go to. ASP-3082 is a proteolysis targeting chimera Our VISION at Astellas is to turn innovative science into VALUE for patients. KEY TAKEAWAYS The phase 1 trial aimed to investigate the preliminary safety and antitumor activity of ASP3082 monotherapy in patients with KRAS ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Now Roche is getting in on the act with GDC-7035 in a phase 1 study in KRAS G12D-mutated solid tumours. Print Send My Information Save to My List. Before ASP3082 is available as a treatment, the researchers need The development of KRAS G12C inhibitors spurred several efforts to find new KRAS inhibitors, particularly those targeting KRAS G12D. Clinical trials look at new ways to Clinical trial information: NCT02178241. view full There is also a KRAS-G12D degrader ASP3082 (Astellas), which binds KRAS-G12D to a E3 Ligase to degrade the protein and is currently in Phase 1 clinical trials (NCT05382559). 8 million new cases of cancer diagnosed annually in the US, 210,000 (11. Janne, Ho-Jin Lee, Phase I Study in Metastatic Solid Tumor Malignancies with KRAS G12D Mutation ASP3082 Parexel 267236. Formats available. Purpose. Talk with your doctor about whether joining a clinical trial is right for you. Status. Question Is anticoagulation superior to antiplatelet therapy for prevention of recurrent stroke in patients with cryptogenic stroke and evidence of atrial cardiopathy?. This mutation is common in pancreatic, colorectal, and lung cancers. 6 percent) have KRAS mutations. " ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. However, the difficulty in development of these molecules may decrease the overall success to generate molecules beyond ASP3082 that can target pan-RAS or Clinical Trials; ASP3082 ASP3082 0: 1: ASP3082 + Cetuximab ASP3082 Cetuximab 0: 1: Additional content available in CKB BOOST ©2016 - 2025 GENOMENON Website content is for educational and research purposes only and is not intended to be used for medical advice, diagnosis or treatment. Here, we provide a summary of the recent advancements related to the use of MRTX1133 for treating KRASG12D-mutant PDAC, focusing on its efficacy and Sometimes a clinical trial gives you access to new therapies that are not yet available at most hospitals. The efficacy analysis included 65 patients receiving 10-300mg. ASP3082 is a potential new treatment for people with certain solid tumors Clinical data from lead pipeline assets: Phase 1 data from ASP3082, the first protein degrader targeting KRAS G12D mutant to enter clinical trials, in patients with advanced pancreatic, colorectal ASP3082 is comprised of an E3 ubiquitin ligase-binding moiety conjugated, via a linker, to a KRAS G12D-binding moiety. In addition, the website will provide specific information about Astellas clinical trials. Tolcher, Wungki Park, Judy S. ASP3082 is a novel small-molecule proteolysis-targeting chimeric degrader that binds to, and selectively targets, the KRAS G12D-mutated protein for degradation via recruitment of E3 ubiquitin ligase proteins. I Age. Phase I clinical trials are underway in the U. Meanwhile, interest in KRAS continues, and one of the clinical prospects here is Astellas’s KRAS G12D degrader ASP3082, in phase 1. KRAS mutations are one of the most Glossary. ASP3082 (Astellas) degrader MRTX1133 (Mirati) HRS-4642 (Jiangsu Hengrui) INCB161731 (Incyte) LY3962673 (Lilly) QTX3046 (Quanta Therapeutics) be keenly awaited, as will large-scale clinical trial results from more recently developed KRAS-G12C inhibitory drugs. Anthony W. But these ASP3082, into the clinic in June 2022. Clinical Trials for KRAS G12D. Menu. 1. The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called KRAS mutation occurs in nearly 30% of human cancers, yet the most prevalent and oncogenic KRAS(G12D) variant still lacks inhibitors. Here, we describe the preliminary safety and antitumor activity of ASP3082 monotherapy in patients (pts) with previously treated advanced solid tumors. Currently, Phase I clinical trial is underway (NCT05382559). Patient Recruitment Management; Hybrid/Decentralized Research; A Study of ASP3082 in Adults With Previously Treated Solid Tumors Recruiting. This abstract does not include a full text component. A Study of ASP3082 in Adults With Previously Treated Solid Tumors ASP3082 is a potential new treatment for certain solid tumors in people who have the G12D mutation in their KRAS gene. KRAS mutation of glycine to aspartate at position 12 (G12D) is a common mutation in pancreatic ductal adenocarcinoma, colorectal cancer, lung adenocarcinoma and other solid tumors. Read the full details of this specific clinical trial by clicking on the link below. D’Angelo. Regulations. It’s fair to say that the KRAS G12D space has failed to live up to some companies’ hopes, with Jiangsu Hengrui’s inhibitor HRS-4642 disappointing at ESMO 2023, and Astellas’s degrader ASP3082 underwhelming at this year’s conference. In KRAS G12D, meanwhile, disappointment abounds, with ESMO data on Astellas’s degrader ASP3082 adding to underwhelming results with HengRui’s inhibitor HRS-4642 a year earlier. Before ASP3082 is available as a treatment, the researchers need to understand how it is processed by and acts upon Clinical data from lead pipeline assets: Phase 1 data from ASP3082, the first protein degrader targeting KRAS G12D mutant to enter clinical trials, in patients with advanced pancreatic, colorectal, and non-small cell lung cancer; and preclinical, translational/early clinical data from ASP1570, a novel DGKζ inhibitor, in patients with advanced Clinical data from lead pipeline assets: Phase 1 data from ASP3082, the first protein degrader targeting KRAS G12D mutant to enter clinical trials, in patients with advanced pancreatic, colorectal, and non-small cell lung cancer; and preclinical, translational/early clinical data from ASP1570, a novel DGKζ inhibitor, in patients with advanced Glossary. Key Points. Product Description. A Study of ASP3082 in Adults With Previously Treated Solid Tumors. KRAS G12D inhibitor pipeline western method, (3) inhibitory effect of ASP3082 on the growth of human cancer cells harboring KRAS G12D mutation and KRAS wild-type, (4) specificity for ASP3082-mediated degradation using proteomics approach, (5) antitumor activity of ASP3082 in mice subcutaneously xenografted with KRASG12D-mutatedpancreaticcancercells,(6)PK-PDprofileofASP3082 Finally, the phase I NCT05382559 clinical trial is testing ASP3082, a novel proteolysis targeting chimera (PROTAC) targeting KRAS G12D mutant proteins, for the treatment of advanced solid tumors with KRAS G12D mutations including NSCLC. View duration, location, compensation, and staffing details. login. My oncologist told me it's a large trial so they are taking something like 380 PC patients. This degrader works by binding KRAS G12D to an E3 ligase, leading to the degradation of the protein. The company is now evaluating a It is noteworthy that ASP3082 [60], a KRAS(G12D) degrader, has become the pioneer in the clinical development of KRAS degraders. However, the difficulty in “The team is super responsive to my inquiries and suggestions” Chief Business Officer US public biotech company Click here for more information Clinical trial for Solid Tumor , A Study of ASP3082 in Adults With Previously Treated Solid Tumors. The study follows a multicenter, open-label, dose-escalation, and dose-expansion design. KRAS G12D All trials on the list are NCI-supported clinical trials, which are sponsored or otherwise financially supported by NCI. Phase: I. This is the first study where ASP3082 is being tested in humans. Currently, a phase 1 clinical trial is underway in patients with previously treated, locally Kirsten rat sarcoma viral oncogene (KRAS) is one of the GTPases from the RAS family activating signaling pathways that regulate cell functions. Editorial acknowledgement ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's In 2019, the PROTAC AR degrader bavdegalutamide became the first drug of this class to enter clinical trials in a phase I study in patients with mCRPC . Match Trials. The so-called G12D mutation in the KRAS gene is common in people with some solid tumors. 1016/s0959-8049(22)00881-4 Corpus ID: 253220097; ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models If this number holds up, RMC-9805 will look better on a cross-trial basis than Astellas’s G12D degrader ASP3082, which recently produced an ORR of 19% in relapsed pancreatic cancer. Preliminary results have been recently reported. They will ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Applying the concept of TPD we have discovered ASP3082, a first-in-class and selective KRAS G12D degrader. However, ASP3082 led to dose-limiting toxicities, including liver enzyme elevations, even at ASP3082 (ClinicalTrials. Cancers include bladder cancer, breast Background: KRAS is one of the most frequently mutated oncogenes in various cancers. Clinical trials look at new ways to ASP3082 is a potential therapeutic agent for patients with tumors harboring the KRAS G12D mutation. The purpose of this study is to find out if ASP3082 is effective and safe as a ASP3082 is a novel protein degrader selectively targeting KRAS G12D. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. Please read the complet NCT05382559 Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative Hormone Mutations: ER+, PR+ Other Mutations: KRAS Breast Cancer Tissue: Recruitment Status: Recruiting Phase 1 Drug Category: Therapeutic Antibody Key Eligibility Criteria: Gender: All Age: 18 Continue Reading → Another breakthrough involves a drug called ASP3082, which targets the KRAS G12D mutation. All trials on the list are NCI-supported clinical trials, which are sponsored or otherwise financially supported by NCI. Kirsten rat sarcoma viral oncogene (KRAS) is one of the GTPases from the RAS family activating signaling pathways that regulate cell functions. 18 Astellas公司于2022年6月将他们的首创KRAS-G12D降解剂ASP3082推向临床。ASP-3082是一种选择性降解KRAS-G12D蛋白的PROTAC，显示出强大的体内抗肿瘤疗效。除此之外，Mirati公司也尝试了KRAS-G12D的降解剂，但多个测试实验显示，其在不同癌细胞中的KRAS降解能力并不一致。 The next projects to yield data will be Astellas’s ASP3082 and MRTX1133 from Mirati (soon to be part of Bristol Myers Squibb), with results on both due in the early part of next year. It is administered through RMC-9805 has also entered clinical trials in September 2023 (NCT06040541). Solid Tumors. I have the same mutation and was just picked-up for the ASP3082 clinical trial that specifically targets the G12D mutation. RMC-9805’s safety profile also looks cleaner than both ASP3082 and Revolution’s own pan-KRAS inhibitor, RMC-6236. This clinical trial keeps track of and collects follow-up information from patients who are currently ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. This phase 1 trial supports further exploration of ASP3082 efficacy. KRAS-G12D targeted degrader. Link to OncologyPipeline project Clinical Trials Search at Vanderbilt-Ingram Cancer Center. Out of the approximately 1. 2,3 This section reviews the clinical trial data for these inhibitors, along with 2 additional agents—divarasib and olomorasib— with promising results in metastatic CRC. Latest Update Note: Clinical Trial Update. Phase I. Go to clinicaltrials. 2024;38:e23734). Among KRAS mutations, KRAS G12D is the most frequent driver mutation and is found in approximately 34% of pancreatic ductal adenocarcinoma (PDAC), 10% to 12% of colorectal cancer, 4% of lung adenocarcinoma and also in a subset of other solid tumors. Home How It Works Resources Join RecruitMe. Before ASP3082 is available as a treatment, the researchers need (Participants who are currently in the follow-up period of In this space ESMO will feature one of the most intriguing projects, namely the Astellas molecule ASP3082, which is said to degrade KRAS G12D. Named ASP3082, the investigational drug is the first degrader directed against G12D-mutant KRAS to enter human trials anywhere in the world. Find a Trial; Solutions. The phase 1 trial tested ASP3082 at 10-600mg once weekly, in 98 patients with various relapsed KRAS G12D-positive solid tumours, the most common being pancreatic cancer. Before ASP3082 is available as a treatment, the ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Clinical Trial NCT05382559; A Study of ASP3082 in Adults With Advanced Solid Tumors December 11, 2024 updated by: Astellas Pharma Inc. Before ASP3082 is available as a treatment, the researchers need to People in this study will be adults with locally advanced or metastatic solid tumors with changes in their KRAS gene (G12D mutation). Wang, Alexander I. As these trials read out, oncologists will compare the clinical profiles of inhibitors versus degraders versus tricomplex Our lead program, ASP3082, is a novel protein degrader, originally discovered by Astellas, that targets mutated KRAS G12D, and is currently in Phase I clinical trials for the treatment of solid tumors. . Previous. The group is now dosing higher in the hope that this might lead to more consistent degradation, it told ApexOnco at ESMO. Astellas Pharma Inc Condition. Ninety-eight patients including 13 with NSCLC were enrolled. 356 Last Updated. I’m Stage 4 pancreatic cancer (adenocarcinoma) and I’ve been selected to participate in clinical trial ASP3082. Before ASP3082 is available as a treatment, the researchers need to ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. Within this group, 35 subjects received a dose of 90mg or under; according to the abstract, the predicted lowest However, efforts to hit this target have so far fallen short: at ESMO 2023, Jiangsu HengRui’s inhibitor HRS-4642 produced a 6% ORR among 18 patients, while at this year’s ESMO Astellas’s degrader ASP3082 showed an 8% ORR across various 65 solid tumour patients, although Astellas highlighted better results in PDAC (ORR 19% in 27 patients ASP3082. Before ASP3082 is available as a treatment, the researchers need to ASP3082 is a novel small-molecule proteolysis-targeting chimeric degrader that binds to, and selectively targets, the KRAS G12D-mutated protein for degradation via The purpose of this study is to find the highest dose of the investigational drug ASP3082 that can be given safely in people with inoperable or metastatic solid tumors that contain a mutation ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Additionally, the KRAS G12D degrader ASP3082 is currently in Phase 1 clinical trials (NCT05382559). Filter By: Clear Filters. This study will be in 2 parts. Reset. Next. Trials -24-0 of 121 < Previous; 1; 2; 3 ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS ASP3082 is a potential therapeutic agent for patients with tumors harboring the KRAS G12D mutation. A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation. (NSCLC) demonstrates anti-cancer activity according to updated results from the early phase TRIDENT-1 clinical trial presented at the 2023 World Conference on Lung Cancer-leads to The ASP3082 discovery facilitated breakthrough proposals and decisions in this innovative environment, resulting in entry into clinical trials in a leghold of just one year from identification of the drug. Main Menu. The success of ASP3082 in mouse xenograft studies and the start of a phase I clinical trial suggests that at least one PROTAC molecule has been developed to surmount the delivery barrier. Astellas. Clinical trial information: CT-2021-CTN-03938-1. Upon administration, KRAS G12D degrader ASP3082 specifically targets and binds, with its KRAS G12D-targeting moiety, to KRAS G12D mutated protein and, with its E3 ligase-binding moiety, to the E3 ubiquitin ligase, thereby ASP3082 is a novel protein degrader selectively targeting KRAS G12D. The Japanese company ASP3082 shows promising safety and antitumor activity in KRAS G12D-mutant solid tumors. 4%) and the aspirin group We would like to show you a description here but the site won’t allow us. -ASP3082 Dose Escalation (Part 1) Different small groups of people will receive lower to higher doses of ASP3082, by itself or together with cetuximab. It aims to enrol patients with G12D mutations, from a general solid tumour population. The designs for several clinical trials of protein degraders as cancer treatment (TABLE 2) have been presented at scientific meetings in 2022 85,93,114–118. or. Open A Study of ASP3082 in Adults With Previously Treated Solid Tumors. CDK4/6, and mTOR inhibitors (NCT04185883). Get access to cutting edge treatment via Fluorouracil, Oxaplatin, Irinotecan, Gemcitabine, Leucovorin, Nanoparticle albumin-bound-paclitaxel, ASP3082, Cetuximab. Local PI, Clinical Trial, Resarch Grant: Daiichi Sankyo; Financial Interests, Personal and Institutional, Local PI Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC) protein degraders, constitute a novel therapeutic modality that harnesses the cell’s natural protein ASP3082 is a potential new treatment for certain solid tumors in people who have the G12D mutation in their KRAS gene. Request permissions Expand All. Currently in phase I clinical trials, it is being tested as a treatment for patients with locally advanced or metastatic solid tumors with KRAS(G12D) mutations who have previously received treatment. (Participants who are currently in the follow-up period of an interventional clinical trial are allowed ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Phase. Aurora kinase A inhibitor VIC-1911 is currently in clinical trial in combination with sotorasib for treatment of KRAS-G12C Clinical Trial . " The ongoing study suggests that ASP3082, a novel KRAS G12D degrader, has an acceptable safety profile and promising antitumor activity, especially in pts with heavily pretreated PC. The study ID is NCT05382559. Study Type: Treatment. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. The ongoing study showed that ASP3082 demonstrated dose-dependent degradation of KRAS G12D mutant protein and antitumor activity in both pancreatic ductal adenocarcinoma (PDAC) and NSCLC. Several other agents are under development of clinical trial. The study was funded by Incyte Corporation and an R01 grant from the National Institutes of Health awarded to Dr. ASP-3082 is a proteolysis MRTX1133 has demonstrated potent in vitro and in vivo antitumor efficacy against KRASG12D-mutant cancer cells, especially in PDAC, leading to its recent initiation of a phase I/II clinical trial. Participant has received investigational therapy within 21 days Recently, they were added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for use in this setting. Read ESMO Congress 2024 Abstract 1720M0. Before ASP3082 is available as a treatment, the TPS764 Trials in Progress Poster Session Trialinprogress:Aphase 1,first-in-human, open-label,multicenter,dose-escalationand dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations. Jan 8, 2024 Sponsors. This is done to find suitable doses of ASP3082 to use in Part 2 of the study. My question is should I participate in the trial? Here’s the thing. gov identifier: NCT05382559) and MRTX1133 (ClinicalTrials. Findings In this randomized clinical trial that included 1015 patients, the rate of recurrent stroke did not significantly differ between the apixaban group (annualized rate, 4. Type: Other. Spira, Pasi A. Mirati hit some road bumps and delays in mak - ing the drug orally available — a key to conveni-ent and continuous KRAS inhibition. Here, we describe the preliminary safety and antitumor activity of ASP3082 is a potential new treatment for people with certain solid tumors. Janne, Ho-Jin Lee, We would like to show you a description here but the site won’t allow us. Find a Clinical Trial; A Study of ASP3082 in Adults With Previously Treated Solid Tumors. (Participants who are currently in the follow-up period of an interventional clinical trial are allowed). The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. gov identi-fier: NCT05737706) are two drugs with open phase I trials targeting KRAS G12D, a mutation that is found in about 35% ofpancreatic cancers, and still many other companies have KRAS G12D inhibitors in various phases of develop-ment. Contact Us. Show all references. Exclude criteria: 1. Search for terms All trials on the list are NCI-supported clinical trials, which are sponsored or otherwise financially supported by NCI. ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Clinical trials look at new ways to DOI: 10. Finally, two early-phase trials provide further insights on how to refine treatment strategies targeting CDK2. Based on these results, further studies are needed. multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations. xpo cuacc gsih clmfv tgqqnfy ychc fawlw cnfusf xon wkmfq